Tarzana Treatment Centers

Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial

Joshua D. Lee, Edward V. Nunes, Patricia Novo et al. · The Lancet · 2017 · 681 citations · Full text

Opioid Epidemic, Comparative Effectiveness, Substance Abuse +10

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

Marc S. Sabatine, Lawrence A. Leiter, Stephen D. Wiviott et al. · The Lancet Diabetes & Endocrinology · 2017 · 578 citations · Full text

Metabolic Syndrome, Hypertension, Diabetes Management +10

American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan – 2015

Yehuda Handelsman, Zachary T. Bloomgarden, George Grunberger et al. · Endocrine Practice · 2015 · 562 citations · Full text

Family Medicine, Diabetes Management, Health Policy +8

Complete Cytoreductive Surgery Is Feasible and Maximizes Survival in Patients with Advanced Epithelial Ovarian Cancer: A Prospective Study

Scott M. Eisenkop, Richard L. Friedman · Gynecologic Oncology · 1998 · 514 citations

Gynecologic Surgery, Surgical Oncology, Gynecological Surgery +10

Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study

Scott M. Eisenkop, Nick M. Spirtos, Richard L. Friedman et al. · Gynecologic Oncology · 2003 · 410 citations

Surgical Oncology, Gynecological Surgery, Advanced Ovarian Cancer +9